Quality-of-Life Test for Skin Disease Fails to Outperform Its Rival in New Study

For more than three decades, dermatologists around the world have relied on a ten-question survey known as the Dermatology Life Quality Index, or DLQI, to measure how deeply skin disease disrupts a patient’s everyday life. The instrument asks about symptoms, feelings, daily activities, clothing choices, social interactions, sport, work or study, personal relationships, sexual difficulties, and the burden of treatment. Each answer is scored, the totals are summed, and the resulting number between zero and thirty is treated as a proxy for suffering. But the DLQI has long carried a known flaw: when a patient marks a question as “not relevant,” that response is scored as zero, which can drag scores downward and make a severely affected patient look better off than they really are. A new cross-sectional observational study published in the Archives of Dermatological Research puts a proposed fix to the test, and the results challenge expectations.

The fix, called the DLQI-Relevant or DLQI-R score, was proposed by Hungarian health economists led by Ferenc Rencz and has been gaining attention in the dermatology literature since 2018. The logic behind it is deceptively simple. Instead of counting “not relevant” answers as zeros, the DLQI-R rescales the questionnaire so that only the items the patient actually answered contribute to the final score. Mathematically, the revised score is calculated as the original DLQI multiplied by ten and divided by ten minus the number of “not relevant” responses. If a patient skips two questions as irrelevant, their raw score is boosted by a factor of ten-eighths, or 1.25. The idea is that a patient who finds several questions irrelevant should not be penalized for it, and their disease burden should be estimated from the domains that genuinely apply to them.

Earlier work suggested this rescaling could matter a great deal. Studies in psoriasis, pemphigus, and morphea found that DLQI-R scoring improved the discriminatory power of the questionnaire, meaning it did a better job of distinguishing patients with different levels of disease burden. Other analyses showed that a high proportion of psoriasis patients give at least one “not relevant” response, raising the possibility of systematic biases in treatment decisions, since DLQI scores are often used to determine eligibility for expensive biologic therapies. A detailed examination of “not relevant” responses in psoriasis published in 2018 flagged exactly this concern, and a 2019 study of United States patients confirmed that these responses measurably influence DLQI values in real-world populations.

Against this backdrop, dermatologists Gülsün Hazan Tabak of Sincan Training and Research Hospital in Ankara and Neslihan Demirel Öğüt of Uşak University in Turkey designed a study to ask whether the DLQI-R truly outperforms the original DLQI when both are compared against objective measures of disease severity. They enrolled 150 adult patients with active psoriasis and 150 patients with chronic urticaria, all diagnosed by a dermatologist. To ensure that every participant had measurable disease activity at the time of assessment, patients whose psoriasis or urticaria activity scores were zero were excluded from the analysis. The final psoriasis group comprised 72 women, or 64 percent, and 39 men, or 36 percent, while the chronic urticaria group included 65 women, or 73 percent, and 24 men, or 27 percent.

Each patient completed the standard DLQI questionnaire, from which the researchers also derived the DLQI-R score using the rescaling formula. For psoriasis patients, disease severity was quantified with the Psoriasis Area and Severity Index, or PASI, a composite measure that scores the redness, thickness, and scaling of lesions across four body regions and weights those scores by the extent of involvement. For urticaria patients, severity was captured with the Urticaria Activity Score over the previous seven days, known as UAS7, which sums daily assessments of the number of wheals and the intensity of itching across a week to yield a weekly activity total. These clinician-graded and patient-recorded severity measures served as the benchmarks against which both quality-of-life scores were judged.

The statistical approach was straightforward and appropriate for the data type. Because DLQI, DLQI-R, PASI, and UAS7 values are not normally distributed in most clinical samples, the researchers used Spearman correlation analysis, a non-parametric method that assesses how well the ranks of two variables move together rather than assuming a linear relationship. Spearman coefficients range from minus one to plus one, with values approaching one indicating that patients with higher disease severity consistently report higher quality-of-life impairment. The team first checked how closely the two questionnaires tracked each other, then compared how strongly each one correlated with the objective severity measure in each disease group.

The first finding was unsurprising: the DLQI and DLQI-R are nearly interchangeable. In the psoriasis group, the two scores showed a strong positive correlation with a Spearman coefficient of 0.981, and in the chronic urticaria group the coefficient was even higher at 0.989, both statistically significant at p less than 0.001. In other words, across these 300 patients, knowing a patient’s DLQI score tells you almost exactly what their DLQI-R score would be. The rescaling formula changes the absolute numbers, but it rarely changes where a patient stands relative to their peers.

The second finding was the one that defied expectations. In the psoriasis group, the correlation between DLQI and PASI was 0.423, while the correlation between DLQI-R and PASI was 0.416, a difference so small it carries no practical meaning. The chronic urticaria group told the same story: DLQI correlated with UAS7 at 0.623 and DLQI-R at 0.608. Contrary to the hypothesis that motivated the study, the DLQI-R was not found to be superior to the original DLQI in assessing disease-related quality of life in either condition. The proposed fix, designed to correct an underestimation of disease burden, did not translate into a stronger relationship with measured disease severity in these two patient populations.

Why might the rescaling fail to deliver an advantage here? One plausible explanation lies in the nature of the correlation itself. A moderate correlation of around 0.42 between PASI and either quality-of-life score reflects a well-known reality of psoriasis: how badly skin looks and how badly it disrupts life are related but far from identical. Visible plaques on covered skin may barely trouble one patient, while mild involvement on the hands or face can devastate another. In that context, a rescaling that boosts scores for patients with many “not relevant” answers may simply redistribute small differences without improving the fundamental alignment between clinical severity and lived experience. The very high correlation between the two questionnaires also suggests that the number of “not relevant” responses, and the corrections applied for them, were too uniform across patients to create meaningful separation between the instruments.

The study’s authors draw a different practical conclusion from their data. Given the high proportion of patients who provided at least one “not relevant” response, they argue that disease-specific health-related quality of life instruments may complement the DLQI by capturing aspects of quality of life that the generic DLQI items do not adequately address. Tools designed specifically for psoriasis or for chronic urticaria can probe the domains that matter most in each condition, from itch intensity and sleep disruption in urticaria to the emotional and social burden of visible plaques in psoriasis. The researchers suggest that adopting disease-specific quality-of-life scales in routine clinical practice would be advantageous, rather than relying solely on a generic instrument or its rescaled variant. The study, approved by the Ethics Committee of Uşak University and conducted in accordance with the Declaration of Helsinki, adds an important cautionary note to a debate that has been building in dermatology for years: before abandoning a familiar measure for a mathematically elegant correction, clinicians should demand evidence that the correction actually improves what matters, and in psoriasis and chronic urticaria, at least, the evidence now says it does not.

Subject of Research: Comparison of DLQI and DLQI-Relevant quality-of-life scores against disease severity in psoriasis and chronic urticaria

Article Title: The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria: a cross-sectional observational study

Article References: Tabak, G. H., & Demirel Öğüt, N. (2026). The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria: a cross-sectional observational study. Archives of Dermatological Research, 318(1), Article 420. https://doi.org/10.1007/s00403-026-04897-w

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04897-w

Keywords: Dermatology Life Quality Index, DLQI-R, psoriasis, chronic urticaria, PASI, UAS7, health-related quality of life, disease severity, Spearman correlation, cross-sectional study, dermatology, patient-reported outcomes